We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phytopharm | LSE:PYM | London | Ordinary Share | GB00BCLY7L40 | ORD 50P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 58.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 58.00 | GBX |
Phytopharm (PYM) Share Charts1 Year Phytopharm Chart |
|
1 Month Phytopharm Chart |
Intraday Phytopharm Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 19/7/2014 | 08:32 | Phytopharm 2011 Thread | 517 |
| 14/10/2013 | 23:36 | Phytopharm 2013 Thread | 62 |
| 14/9/2012 | 17:02 | Only worth 4p on fundamentals | 6 |
| 07/3/2012 | 10:01 | PHYTOPHARM | 68 |
| 07/3/2012 | 10:00 | What happened to PHYTOPHARM!!! | 23 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 28/9/2013 18:30 by gerhart One of the new directors buys a few...Think we are going to move up fast when the deal is rubber stamped (we've a bit of ground to make up anyway to pre-suspension price. Typical MMs.) |
Posted at 26/9/2013 23:26 by aishah Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", or the "Company") today announces that terms have been agreed for the conditional acquisition (the "Acquisition") of IXICO Limited ("IXICO"), a medical technology and diagnostics company. The aggregate consideration for the Acquisition is to be satisfied by the initial issue of 8,014,403 New Ordinary Shares on Admission and the proposed issue of 465,350 New Ordinary Shares as a result of the outstanding share options under the IXICO unapproved share option share scheme. Based on the Phytopharm closing share price of 20 May 2013 immediately prior to its suspension, the aggregate consideration is valued at approximately GBP5.6 million. |
Posted at 24/9/2013 21:32 by gerhart We are a little below the equivalent price before suspension. But hopefully that will change when the deal is passed in a few weeks and we get some interest in the "new" company. So no one has probably made any money since the share price crash. GLA. |
Posted at 23/9/2013 07:12 by skinny Portfolio company IXICO expands into digital healthcareImperial Innovations Group plc (AIM: IVO, "Innovations") portfolio company IXICO Limited, a medical imaging analysis company, is to be acquired by Phytopharm plc (AIM: PYM) in a proposed reverse takeover announced today. The enlarged Phytopharm group, to be renamed IXICO plc, will benefit from a strengthened balance sheet to grow its clinical trial services business and to bring new technology solutions to the diagnosis of dementia and other conditions. The newly-quoted IXICO plc will use the new ticker 'IXI'. Innovations maintains its support for IXICO and as part of this transaction has purchased a small parcel of shares; following completion of this transaction it will hold a 11.518% shareholding in IXICO plc. IXICO has established itself as a leading provider of medical imaging analysis services in the clinical trials market. It is expanding into the 'digital healthcare' space with products to support dementia diagnosis. Its vision is to build on its credibility internationally to position itself as a 'Brain Health Company' and to bring innovative technologies to those involved in researching and treating serious brain diseases enabling them to help patients more quickly. Maina Bhaman, Director of Healthcare Ventures at Innovations, will be joining the IXICO plc board on completion. |
Posted at 23/9/2013 07:11 by skinny Proposed acquisition of IXICO LimitedProposed Issue of up to 8,479,753 New Ordinary Shares in the Company Proposed change of name to IXICO plc Admission of the Enlarged Issued Share Capital to trading on AIM Renewal of Shareholder Authorities and Notice of General Meeting Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", or the "Company") today announces that terms have been agreed for the conditional acquisition (the "Acquisition") of IXICO Limited ("IXICO"), a medical technology and diagnostics company. The aggregate consideration for the Acquisition is to be satisfied by the initial issue of 8,014,403 New Ordinary Shares on Admission and the proposed issue of 465,350 New Ordinary Shares as a result of the outstanding share options under the IXICO unapproved share option share scheme. Based on the Phytopharm closing share price of 20 May 2013 immediately prior to its suspension, the aggregate consideration is valued at approximately £5.6 million. Following completion, it is expected that Phytopharm shareholders will own approximately 45 per cent and that IXICO shareholders will own approximately 55 per cent of the Fully Diluted Enlarged Issued Share Capital. In view of the size of IXICO in relation to the Company, the Acquisition is classified as a reverse takeover under the AIM Rules and is therefore conditional, inter alia, on the approval of Shareholders in a general meeting. A copy of the admission document along with the notice of General Meeting is being sent out to shareholders shortly and will be available on the Company's website www.phytopharm.com. The Directors of Phytopharm consider that IXICO will provide a platform from which to create value for Shareholders and will provide a different risk profile to the Company's business model. Upon completion of the Acquisition, Phytopharm plc will change its name to IXICO plc with the new ticker "IXI". |
Posted at 18/9/2013 07:28 by ewads From PYM Website:-'Application will be made to the London Stock Exchange plc for the Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the Ordinary Shares will become effective on or around 4 September 2013.' Anyone have an update? |
Posted at 09/8/2013 07:05 by skinny During the period· Following the completion of a strategic review on 21 May 2013 the company announced it had signed heads of terms in connection with the possible acquisition of a revenue generating UK-based private company in the healthcare sector (the "Target"). · On 19 July 2013 the Company announced the proposed cancellation of the Company's listing on the Official List and admission to trading on AIM which was approved by shareholders on 5 August 2013. · Upon Admission to AIM the Company will be classified as an Investing Company and shareholders have approved the Company's investing policy which is set out below. · Admission to trading on AIM is expected to take place at 8.00 am on 4 September 2013. The Company's shares are expected to remain suspended upon Admission to AIM until the Company publishes an AIM admission document in respect of the acquisition of the Target or announces that discussions have been terminated. · As required by the AIM Rules the Company issued a Schedule 1 announcement on 6 August 2013 and published via its website additional information required in connection with the Admission to AIM. · The Company has also received shareholder approval for a share capital consolidation in order to create a share capital base which is more consistent with that of companies of a similar size. The share capital consolidation will take place immediately prior to Admission to trading on AIM. The existing ordinary shares will be consolidated on the basis of one consolidated ordinary share for every fifty existing ordinary shares. · Our financial performance from 1 April 2013 to date continues to be in line with our expectations. As at 31 July 2013 the Group had unaudited money market investments and cash and cash equivalents of £5.15 million. Following the failure of Cogane in a Phase II clinical trial earlier in the year we have significantly curtailed expenditure in order to preserve the Company's financial resources. Investing Policy The Directors intend to pursue suitable corporate acquisitions offering the potential to deliver a favourable return to Shareholders over the medium term, primarily in the form of capital gain. The Company's Investing Policy is to invest in businesses that typically have attributed to them some or all of the following characteristics: · Healthcare sector: · Revenue generating or near revenue generating; · Embedded or protected IP; · UK based; · Capable of significant growth potential; and · A credible management team. |
Posted at 24/7/2013 20:52 by gerhart No we're not going to be disappearing anywhere, just hope the shareholder with a foot in both camps (its in RNS) values their PYM buddies at least as much as the target buddies.On the RNS, same with lots of these, but the repetition is endless! |
Posted at 22/7/2013 20:11 by ewads moneymachine2 - looks like I was wrong!Phytopharm plc : Cancellation of Listing and Admission to AIM 19/07/2013 | 09:38am 19 July 2013 Proposed Cancellation of Listing and Admission to AIM Phytopharm plc announces that it will today post a circular to shareholders convening a General Meeting to be held at the Company's offices, Lakeview House, 2 Lakeview Court, Ermine Business Park, Huntingdon, Cambridgeshire PE29 6UA at 10 a.m. on 5 August 2013 at which it will seek shareholder approval for the proposed cancellation of admission to the premium segment of the Official List and to trading on the London Stock Exchange's Main Market for listed securities and detail its intention to apply for admission to AIM, adoption of an Investing Policy and undertake a share capital consolidation. The circular will be available shortly on the Company's website at www.phytopharm.com and will be submitted to the National Storage Mechanism where it will shortly be available at www.morningstar.co.u Background to and reasons for Cancellation and Admission On 21 May 2013, the Company announced that it had signed heads of terms in connection with the possible acquisition of a revenue generating UK-based private company in the healthcare sector. Whilst the Board initially was planning to seek shareholder approval for the acquisition of the a revenue generating UK based private company in the healthcare sector at a General Meeting to be convened in due course, after which the Company also expected to delist from the Main Market and seek admission of the enlarged share capital to trading on AIM, the Board and the Target believe that there are a number of benefits from transferring the Company's quote to AIM before a definitive agreement is reached with the Target. Upon Admission to trading on AIM, the Board expects the Company to be classified as an Investing Company (defined as an AIM company which has as its primary business or objective, the investing of its funds in securities, businesses or assets of any description). The Board believes that AIM is a more appropriate market for a company of Phytopharm's size and that a transfer of the Existing Ordinary Shares to trading on AIM should lead to lower ongoing costs associated with being a publicly quoted company and a simplification of the Company's administrative and regulatory requirements. It also believes that AIM will offer greater flexibility, particularly with regard to corporate transactions, and should therefore enable the Company to agree and execute certain transactions more quickly. In addition, the Company intends to consolidate its existing ordinary shares on the basis of 1 consolidated ordinary share for every 50 Existing Ordinary Share in order to create a share capital base which is more consistent with that of companies with a similar size. |
Posted at 21/5/2013 09:26 by greedfear Investors in PYM do not lose their investment. If you find this difficult to understand than you could compare this to PYM buying (the shares of) an another company and paying with PYM shares.{I like it. The new company (PYM + the other) keep the cash, are revenue generating while PYM tax losses can still be carry forward (provided the new shareholders in the new company hold less than 25%)} |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
